跳至主要内容

CROs call for better ways to leverage investigative site relationships

Improving investigative site relationships in 2015 is a top priority for pharma and CRO (contract research organization) execs, according to a roundtable recently hosted by the Tufts Center for the Study of Drug Development.

Specifically, Tufts found that soliciting input from clinical research sites on protocol design, providing payments directly to study patients, sharing their development plans, and providing feedback via quality metric scorecards can help sponsors and CROs mitigate challenges.

Patient recruitment remains the largest challenge clinical research sites face, with more than half of sites saying sponsors and CROs they work with don’t provide sufficient information about the studies they’re working on.

Also posing a burden on sites is the way sponsors/CROs pay them. According to the Society for Clinical Research Sites (SCRS), in 2014 about 65% of clinical research sites had less than three months of operating cash -- a slight increase from 57% in 2012. On average, sites also pay for patient visits as a study rolls out, but the sites don’t typically receive pay­ment from sponsors/CROs until about five to six months after the work is completed.

And to help guard against unpredictable site performance, sponsors and CROs have reduced the average num­ber of randomized patients per trial expected of each engaged investigative site, according to Tufts, though this has resulted in an unintended consequence of limiting sites’ ability to operate efficiently.

Participants in the roundtable said they are looking to solicit more input from investigative sites to guide study planning and execution; incorporate anticipated changes in the site landscape, such as the integration of clinical research into patient care at large health institutions; and establish new relationship support mechanisms.

Tufts gives the example of having a medical monitor available 24/7 to answer questions when patients are at an active trial site can help sponsors and CROs ensure strong site performance.

New Paradigm

A CRO that conducts clinical trials globally also suggested to Tufts that strategic site relationships are creating a “new par­adigm” in site management because strategic partnerships between sponsors and CROs are adding to CROs’ responsibility to select and manage sites.

“Sites that want to build their business over the medium- to long-term are responding by adopting best practices, including better management of data and investing in their relationships with CROs,” Tufts notes. From a CRO’s perspective, criteria that make a site suitable for a strategic relationship include:

  • The ability to solve problems quickly, provide effective protocol and technical training;
  • Ensure clinical trial materials and investigational drugs arrive at the site on time; and
  • Ensure that the clinical research associate is kept abreast of the protocol and therapeutic area.

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential tox...
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d...
发表评论
阅读全文

Enzyme Activity Assay Service

  Enzymatic assay Lance Assay Alphascreen Assay Z’-LYTE Assay Adapta Assay Kinase-Glo Assay ADP-Glo Assay Ligand Binding Assay ELISA Assay HTRF Assay Enzyme activity assays  are laboratory methods for measuring enzymatic activity. They are vital for the study of enzyme kinetics and enzyme inhibition. Enzyme units : Amounts of enzymes can either be expressed as molar amounts, as with any other chemical, or measured in terms of activity, in enzyme units. Medicilon provides various  enzyme activity assays  for  kinases , phosphatases, proteinases, deacetylase, peptidase, esterase, and other enzymes. Our line of well-characterized immunoassays and biochemical kits ensures accurate and reproducible results. Enzyme is a  large category of bio-molecules  that catalyze various biological processes including metabolic processes, cellular signaling and regulation, cell division and apoptosis. Enzymatic reactions convert substrate molecules into chemically modifi...
发表评论
阅读全文